Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
June 14, 2024 07:30 ET
|
Cogent Biosciences, Inc.
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains...
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024 07:30 ET
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
June 14, 2024 06:59 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314
June 14, 2024 06:23 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides in-depth insights into the...
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
June 14, 2024 06:00 ET
|
Shattuck Labs, Inc.
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...
1st Quarter Results
June 14, 2024 04:33 ET
|
Oxford Technology 2 VCT plc
14 June 2024 Oxford Technology 2 VCT Plc (the "Company") Legal Entity Identifier: 2138002COY2EXJDHWB30 1st Quarter Results Oxford Technology 2 VCT...
Global Hookah Tobacco Market Report 2024-2028: Growing Popularity of Hookah Bars, Lounges and Cafe Culture and Rising Number of Organized Retailing Outlets Drives Market Growth
June 14, 2024 04:08 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Global Hookah Tobacco Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The hookah tobacco market is forecasted to grow by...
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024 03:00 ET
|
Beam Therapeutics
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting...